Genitourinary Cancers Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials:

Urothelial Cancer
Prostate Cancer
Renal Cell Cancer

Urothelial

A Study of Enfortumab Vedotin Alone or with Other Therapies for Treatment of Urothelial Cancer (EV-103)

Treatment: Enfortumab Vedotin
PI: Ian Anderson, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03288545

Prostate

A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)

Treatment agent: Rucaparib (PARPi)
PI: Wes Lee, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT02975934

Renal Cell

A Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Carcinoma

Treatment: Everolimus
PI: Ian Anderson, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links: clinicaltrials.gov NCT No: NCT04195750